Avantor Inc. (NYSE:AVTR) stock is trading after reporting worse-than-expected third-quarter 2025 adjusted earnings of 22 cents, below the consensus of 23 cents.

The life science tools company reported sales of $1.62 billion, slightly below the consensus of $1.65 billion. Sales fell 5.3% year over year. Foreign currency translation had a positive impact of 2.2%, and M&A had an adverse impact of 2.8%, resulting in a 4.7% organic sales decline.

Laboratory Solutions sales were $1.09 billion, a reported 6.4% decrease. Sales decreased by 4.9% organically. The segment sees continued end-market uncertainty related to basic research funding.

Also Read: Avantor Stock Jumps As Activist Investor Urges Sale, Board Shake-Up, And Cost Cuts

Bioscience Production sales were $527.3 million, a reported decrease of 2.9%, ...